🇺🇸 FDA
Patent

US 12065506

Anti-TMPRSS2 antibodies and antigen-binding fragments

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12065506 (Anti-TMPRSS2 antibodies and antigen-binding fragments) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/54, A61K9/0019